1150308-67-0

Basic information

• Product Name: tert-butyl 4-(2-chloro-5-nitrobenzyl)piperazine-1-carboxylate
• Synonyms: tert-butyl 4-(2-chloro-5-nitrobenzyl)piperazine-1-carboxylate
• CAS NO: 1150308-67-0
• Molecular Weight: 355.821
• Mol File: 1150308-67-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: tert-butyl 4-(2-chloro-5-nitrobenzyl)piperazine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-(2-chloro-5-nitrobenzyl)piperazine-1-carboxylate(1150308-67-0)
• EPA Substance Registry System: tert-butyl 4-(2-chloro-5-nitrobenzyl)piperazine-1-carboxylate(1150308-67-0)

Safety Data

• Hazardous Substances Data: 1150308-67-0(Hazardous Substances Data)

Upstream product

• 6361-21-3 2-chloro-5-nitrobenzaldehyde 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 

Downstream Products

• 769961-14-0 tert-butyl 4-(5-amino-2-chlorobenzyl)piperazine-1-carboxylate 
• 1446113-47-8 tert-butyl 4-(2-chloro-5-((6-methyl-5-nitroisoquinolin-1-yl)amino)benzyl)piperazine-1-carboxylate 
• 1446113-48-9 tert-butyl 4-(5-((5-amino-6-methylisoquinolin-1-yl)amino)-2-chlorobenzyl)piperazine-1-carboxylate 
• 1446112-28-2 tert-butyl 4-(5-((5-(4-aminothieno[3,2-d]pyrimidine-7-carboxamido)-6-methylisoquinolin-1-yl)amino)-2-chlorobenzyl)piperazine-1-carboxylate 
• 1446112-30-6 4-amino-N-(1-((4-chloro-3-(piperazin-1-ylmethyl)phenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide hydrochloride 

Relevant articles and documents

THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES

Provided are a thieno[3,2-d]pyrimidine derivative of formula (I) or a pharmaceutically acceptable salt thereof having inhibitory activity for protein kinase, and a pharmaceutical composition comprising same for prevention and treatment of abnormal cell growth diseases.

FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS

The invention relates to compounds of the formulae (I) to (III) wherein the substituents are as defined in the specification. These compounds have kinase inhibitory activity, such as VEGFR/KDR inhibitory activity. Accordingly, the compounds of the formulae (I) to (III) would be useful in the prevention and treatment of angiogenesis related disorders, ophthalmological conditions, proliferative diseases, inflammatory diseases, and other pathological conditions as described in the specification.